JPMorgan Chase & Co’s Nurix Therapeutics NRIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $575K | Buy |
50,482
+4,792
| +10% | +$54.6K | ﹤0.01% | 3997 |
|
|
2025
Q1 | $543K | Buy |
45,690
+14,795
| +48% | +$176K | ﹤0.01% | 3955 |
|
|
2024
Q4 | $582K | Sell |
30,895
-37,253
| -55% | -$702K | ﹤0.01% | 4082 |
|
|
2024
Q3 | $1.53M | Buy |
68,148
+31,352
| +85% | +$704K | ﹤0.01% | 3424 |
|
|
2024
Q2 | $768K | Buy |
36,796
+2,472
| +7% | +$51.6K | ﹤0.01% | 3643 |
|
|
2024
Q1 | $505K | Sell |
34,324
-13,666
| -28% | -$201K | ﹤0.01% | 3951 |
|
|
2023
Q4 | $495K | Sell |
47,990
-4,901
| -9% | -$50.6K | ﹤0.01% | 3914 |
|
|
2023
Q3 | $416K | Buy |
52,891
+64
| +0.1% | +$503 | ﹤0.01% | 3819 |
|
|
2023
Q2 | $528K | Buy |
52,827
+17,092
| +48% | +$171K | ﹤0.01% | 3735 |
|
|
2023
Q1 | $317K | Sell |
35,735
-53,361
| -60% | -$473K | ﹤0.01% | 4065 |
|
|
2022
Q4 | $979K | Buy |
89,096
+60,822
| +215% | +$668K | ﹤0.01% | 3361 |
|
|
2022
Q3 | $368K | Sell |
28,274
-101,251
| -78% | -$1.32M | ﹤0.01% | 3897 |
|
|
2022
Q2 | $1.64M | Buy |
129,525
+9,009
| +7% | +$114K | ﹤0.01% | 3136 |
|
|
2022
Q1 | $1.69M | Buy |
120,516
+30,664
| +34% | +$429K | ﹤0.01% | 3288 |
|
|
2021
Q4 | $2.6M | Buy |
89,852
+31,867
| +55% | +$922K | ﹤0.01% | 3054 |
|
|
2021
Q3 | $1.74M | Buy |
57,985
+29,148
| +101% | +$873K | ﹤0.01% | 3263 |
|
|
2021
Q2 | $765K | Buy |
28,837
+16,938
| +142% | +$449K | ﹤0.01% | 3779 |
|
|
2021
Q1 | $370K | Buy |
11,899
+6,668
| +127% | +$207K | ﹤0.01% | 4197 |
|
|
2020
Q4 | $172K | Buy |
5,231
+1,091
| +26% | +$35.9K | ﹤0.01% | 4186 |
|
|
2020
Q3 | $138K | Buy |
+4,140
| New | +$138K | ﹤0.01% | 3917 |
|